SAUMYA DAS

SAUMYA DAS


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2022 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
JRJAYARAMAN RAJANGAM
JAYARAMAN RAJANGAM
NSNavaneetha Krishnan S
Navaneetha Krishnan S
NPNarahari Narayan Palei
Narahari Narayan Palei
SBShvetank Bhatt
Shvetank Bhatt
MDManas Kumar DAS
Manas Kumar DAS
KMKrishnapillai Mathusoothanan
Krishnapillai Mathusoothanan
The study aimed to explore the in vivo protective potential of rosuvastatin (ROSS), an oral antihyperlipidemic drug against doxorubicin (DOXO) induced cardio toxicity in rats. Cardiac toxicity was induced by DOXO injection (10 mg/kg, i.p.), once on the 20th day of the experiment. Except for the control rats, all were received DOXO and the study was continued for up to 21 days. The influence of ROSS on acute treatment was analyzed by quantification of cardiac marker enzymes such as creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH) and liver marker enzymes like aspartate aminotransferase (AST), alanine aminotransferase (ALT) along with the measurement of in vivo antioxidants like superoxide dismutase and catalase. To observe histological changes of myocardial tissue hematoxylin and eosin staining were used. Acute administration of DOXO resulted in a marked rise of cardiac marker enzymes that confirms the myocardial damage compared to control animals whereas administration of ROSS (10 mg/kg, p.o.) resulted in the significant reduction of CK-MB, LDH levels (p<0.05) and AST, ALT levels to a remarkable extent. Moreover, ROSS administration significantly increased the activities of various in vivo antioxidant levels. From the results, the acute administration of ROSS showed significant cardioprotective property, which was evidenced by a significant reduction of cardiac and liver marker enzymes along with significant improvement of in vivo antioxidant activities. Furthermore the results were supported with histopathological observations. Hence, it can be concluded that cardioprotective potential of ROSS may be through attenuation of oxidative stress by modulating oxidative damage in rats.

28 December 2023 in Plant Science Today
Verified
Journal Article
Open access
PDF file
AMApoorva Mishra
Apoorva Mishra
SDSAUMYA DAS
SAUMYA DAS
SKSoni Kumari
Soni Kumari
Alzheimer's Disease (AD), a neurological ailment, mostly affects the older population all around the world. The rational therapies show limited efficacy, adverse effects, and poor patient compliance; therefore, herbal drugs are considered a suitable supplement to the drug therapy for the treatment of AD. According to research, herbal drugs reduce symptoms of AD and also improve brain functioning through the inhibition of beta amyloid, gamma-secretase, and acetylcholine, along with the regulation of antioxidants and the activation of alpha-secretase. Various herbal plants like Salvia officinalis L., Bertholletia excelsa L., Withania somnifera L., and Urtica dioica L. help slow down the progression of AD by scavenging free radicals, inhibiting lipid peroxidation, beta amyloid and tau phosphorylation. Beta sitosterol, a phytosterol found abundantly in plants, has the ability to cross the Blood Brain Barrier and thus acts as a bioactive constituent in circumventing various neurological disorders. Numerous in vitro and in vivo investigations indicate that beta sitosterol shows immunomodulatory, lipid-lowering, as well as antioxidant properties. The plant sterol, beta sitosterol, has the capacity to decrease beta-amyloid platelet synthesis, indicating that it might be helpful in the treatment and prevention of AD. Treatment with beta-sitosterol can lessen plaque burden and also enhance spatial learning and recognition abilities in patients suffering from AD.

20 May 2025 in Health Leadership and Quality of Life
Verified
Journal Article
Open access
PDF file
DCDevraj Singh Chouhan
Devraj Singh Chouhan
SDSAUMYA DAS
SAUMYA DAS
PGPrateek Garg
Prateek Garg
NMNagireddy Mounika
Nagireddy Mounika
SSSwamyvel Sethuraman
Swamyvel Sethuraman
NSNittin Sharma
Nittin Sharma
Agoraphobia with panic disorder (PD) is a phobia-anxiety condition that makes sufferers avoid situations or locations where it could feel embarrassed or be unable to leave or get help in case of a PD. Agoraphobia has been associated with recurrent PD syndrome over the last 50 years, and in many instances, it is regarded to represent the normal progression or complication of PD. Even though agoraphobia with PD is quite common in patients receiving primary care, medical professionals often fail to recognize and adequately treat the disease. These medications alleviate the usually associated depression symptoms as well. Selective Serotonin Reuptake Inhibitor (SSRI) are well-tolerated and effective for both anxious and depressive symptoms, making the primary option for treating agoraphobia with PD in the short, medium, and long term. SSRIs which are less likely to cause withdrawal symptoms after abrupt discontinuation should be used for long-term prophylaxis. Tricyclic Antidepressant (TCA) can be a second-line therapy for PD if SSRIs don't work, although venlafaxine hasn't been researched long-term. High-potency medications are advantageous choices for short-term therapy since ithas been shown to have a quick start of anti-anxiety action, having favorable benefits. Cognitive-Behavioral Therapy (CBT), which is the non-pharmacological approach that has gotten the most research, can be employed with a variety of patients depending on how easily it is accessible.

20 June 2024 in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Verified
Journal Article
Open access
PDF file
BSBhawana Sharma
Bhawana Sharma
SDSAUMYA DAS
SAUMYA DAS
AMAVIJIT MAZUMDER
AVIJIT MAZUMDER
DRDeepraj Singh Rautela
Deepraj Singh Rautela
Pankaj Kumar TyagiPankaj Kumar Tyagi
Pankaj Kumar Tyagi
NKNavneet Khurana
Navneet Khurana
Background: Alzheimer's disease (AD) is marked by cognitive decline along with the presence of mental symptoms, most notably psychosis. Although antipsychotic drugs are commonly recommended to treat these symptoms, there is ongoing discussion on the safety and effectiveness of these drugs in AD patients. The therapeutic management of Alzheimer’s disease-related psychosis (ARP) is hampered by its limited therapy options, determining the precise brain regions in Alzheimer’s patients with understanding of the neurological substrates implicated in ARP. While new therapies including brexpiprazole and atypical antipsychotics present promising therapeutic choices, practical implementation and potential upcoming therapies approaches is discussed along with mechanism-based understanding of different neurotransmitters with pharmaceutical therapies. Our objective is to contribute to more efficient and individualized treatment approaches by offering a thorough resource for medical professionals and researchers working in the field of managing and researching psychosis associated with AD.Results: The examination containing new data supporting newer therapeutic approaches that target receptors and providing better safety and effectiveness characteristics. This study point out gaps in our existing understanding and make recommendations for future research, emphasizing the necessity of clinical trials created especially for psychotic Alzheimer’s patients. Secondly, the neurochemical and neuropathological bases of ARP, with a focus on changes in the dopamine, serotonin, and glutamate systems of neurotransmitters are also described in detail. Different pharmacodynamics antipsychotic medications are covered in later sections of this paper, with an emphasis on how these medications' interactions with certain neurotransmitter receptors may affect their therapeutic efficacy and side-effects profile.Conclusion: The review article summarizes the most recent findings regarding the contribution of neurotransmitter receptors to the effectiveness of antipsychotic drugs in the management of ADP. We provide a thorough overview of second-generation (atypical) antipsychotics, emphasizing how their unique affinity for neurotransmitter receptors influences their clinical application in psychosis associated with AD. The difficulties of treating Alzheimer’s with antipsychotics are also covered in this study, including the potential for cognitive impairment to worsen, the emergence of extrapyramidal symptoms, and other unfavorable effects. New approaches to studying and treating ARP including neuroinflammation-targeting medicines, transcranial magnetic stimulation (TMS), cerebrospinal fluid (CSF) biomarkers, and muscarinic acetylcholine receptor (mAChR) agonists like xanomeline. Reducing psychosis through treatment options could be improved by knowledge of N-methyl-D-aspartate glutamate receptors (NMDAR) hypofunction processes in gamma-aminobutyric acid (GABAergic) neurons.

1 July 2025 in Central Nervous System Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SJSanidhya Jain
Sanidhya Jain
AMAVIJIT MAZUMDER
AVIJIT MAZUMDER
SDSAUMYA DAS
SAUMYA DAS
Pankaj Kumar TyagiPankaj Kumar Tyagi
Pankaj Kumar Tyagi
MCMVNL Chaitanya
MVNL Chaitanya
Mild Cognitive Impairment (MCI) is swiftly emerging as a prevalent clinical concern within the elderly demographic. Willoughby spearheaded the pioneering investigation into the evolution of memory decline spanning from the age of 20 to 70. Employing a computerized substitution examination, he pinpointed a zenith in memory prowess at the age of 22, signifying the shift from infancy, succeeded by a gradual decline in later years in 1929. Cognitive impairment impacts various facets, encompassing cognition, memory, perceptual acuity, and linguistic proficiency. Compelling evidence indicates that genetic, dietary, and metabolic factors influence the trajectory of cognitive decline in this patient cohort. In addition to the widely recognized influence of the Mediterranean diet on cognitive function, numerous studies have delved into the potential impact of diverse phytochemicals on cognitive deterioration. Many of these compounds are renowned for their inflammation reducer or free-radical scavenger properties, coupled with their commendable acceptability and defense profiles. Phytochemicals sourced from medicinal plants play an essential role in upholding the intricate chemical equilibrium of the brain by modulating receptors linked to crucial inhibitory neurotransmitters. Across the annals of historical medicinal traditions, a multitude of plants have been cataloged for their efficacy in mitigating cognitive disorders. This study presents a concise examination of distinct medicinal herbs, highlighting their neuroprotective phytochemical components such as fatty acids, phenols, alkaloids, flavonoids, saponins, terpenes, and beyond. The principal objective of this inquiry is to meticulously inspect and provide discernment into the extant evidence concerning phytochemicals exhibiting clinically demonstrable effects on cognitive decline.

1 February 2025 in Letters in Organic Chemistry
Verified
Journal Article
Closed access
PDF file
SSSadhana Sharma
Sadhana Sharma
CMChandana Majee
Chandana Majee
RMRUPA MAZUMDER
RUPA MAZUMDER
KRKavita Rana
Kavita Rana
SPSwarupanjli Padhi
Swarupanjli Padhi
SSSACHIN Kumar SINGH
SACHIN Kumar SINGH
Oxadiazole is an organic compound featuring a heterocyclic ring housing carbon, oxygen, and nitrogen atoms. Due to their heightened stability in biological environments, oxadiazole rings exhibit significant biological activities, effectively addressing health challenges like infectious diseases and chronic conditions in medicinal chemistry. The main objective of this review is to discuss various synthetic approaches related to oxadiazole and its derivatives, along with their biological activities. The diverse reactivity positions oxadiazole as a valuable building block in organic synthesis, with derivatives exhibiting promising pharmacological activities. It involvesa systematic literature review, critical analysis, and synthesis of existing research This review comprises the everexpanding chemical knowledge but also holds significant implications for drug development. The various synthetic approaches, such as Suzuki-Miyaura, Stille coupling [3+2] cycloaddition reaction, and many more methods used for the synthesis of oxadiazole through different schemes, have been discussed thoroughly. This review also concisely associated the pharmacological activities of new oxadiazole and its derivatives, such as prenoxdiazine, dapagliflozin, nesapidil, pleconaril, and so on. This review highlights the importance of continued research into the structure-activity relationships of oxadiazole derivatives, paving the way for developing novel and more potent therapeutic agents.